Alumis eyes late-stage lupus study despite trial miss

Alumis Inc. (ALMS) Discusses Phase IIb LUMUS Trial Results and Subgroup Insights in Type 1 Interferon-Driven Diseases Transcript

Alumis Inc. (ALMS) Discusses Phase IIb LUMUS Trial Results and Subgroup Insights in Type 1 Interferon-Driven Diseases September 1, 2026 8:30 AM EDTCompany...

Alumis Lupus Trial Misses Main Goals, but High-Interferon Subgroup Shows Promise

Alumis (NASDAQ:ALMS) said its Phase II LUMUS trial of envudeucitinib in systemic lupus erythematosus, or SLE, did not meet its primary or key secondary endpoints in the overall study population. However, the company said pre-specified analyses showed clinically meaningful responses among patients wi

Alumis eyes late-stage lupus study despite trial miss - Regional Media News

Sept 1 (Reuters) - Alumis said on Tuesday it plans to advance its experimental drug for a type of immunity-related condition in a smaller subset of patients, even after the treatment failed to meet the main goal of a mid-stage trial. Its shares slumped more [...]

Alumis eyes late-stage lupus study despite trial miss

Sept 1 (Reuters) - Alumis said on Tuesday it plans to advance its experimental drug for a type of immunity-related condition in a smaller subset of patients, even ​after the treatment failed to meet the main goal ‌of a mid-stage trial. Its shares slump...

Alumis’ TYK2 drug fails in key lupus study

Though Alumis still sees a path forward in lupus, the result made its drug the latest TYK2 blocker to struggle in conditions beyond psoriasis and psoriatic arthritis. 

Alumis (ALMS) Stock Crashes Over 50% Following Lupus Trial Disappointment

Alumis (ALMS) stock plummeted 56% after Phase 2b lupus trial failure. IFNGS-high subgroup showed promise. Psoriasis NDA filing still planned for Q4 2026. The post Alumis (ALMS) Stock Crashes Over 50% Following Lupus Trial Disappointment appeared first on Blockonomi.